CXCL8 and gastric cancer: One study found that IL-8, an inflammatory cytokine, promotes chemoresistance to cisplatin in human gastric cancer via NF-κB activation and suggests targeting IL-8 to inhibit the downstream effects of NF-κB and enhance response to chemotherapy [69].